KIM-ANH DO to Remission Induction
This is a "connection" page, showing publications KIM-ANH DO has written about Remission Induction.
Connection Strength
0.055
-
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
Score: 0.012
-
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar; 21(3):480-8.
Score: 0.011
-
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
Score: 0.011
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
Score: 0.010
-
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
Score: 0.008
-
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia. 1990 May; 4(5):316-20.
Score: 0.003